Corvus Pharmaceuticals PEG Ratio

Corvus Pharmaceuticals (CRVS) currently reports a PEG ratio of 12.68. That is above the Healthcare sector average of 11.64. Use the charts on this page to explore Corvus Pharmaceuticals's PEG ratio history and peer comparisons.

Corvus Pharmaceuticals's PEG ratio of 12.68 is higher than the Healthcare sector average of 11.64. That is roughly 8.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Corvus Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 12.68, CRVS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 12.68, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.64. From there, open related valuation or income-statement pages for Corvus Pharmaceuticals, and consider following CRVS for alerts when major investors trade the stock.

Corvus Pharmaceuticals is classified in the Healthcare sector. On PEG ratio, it currently shows 12.68 versus a sector average near 11.64. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRVS with unrelated industries.